Drugs / Begacestat
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00959881 | Aug → Nov 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00547560 | Aug 2007 → Oct 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00479219 | May → Oct 2007 | Alzheimer disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00441987 | Feb 2007 → Jul 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Begacestat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959881 ↗ |
| Known as | GSI-953 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00479219 ↗ |
| Modality | Small molecule | — CHEMBL463981 ↗ |
| Route | Oral | “single oral dose of GSI-953” NCT00441987 ↗ |